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The objective of this study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of S-1, an oral
fluorouracil derivative, combined with gemcitabine, the current standard treatment for advanced pancreatic cancer (APC). The
subjects were histopathologically proven APC patients with distant metastasis. S-1 was administered orally twice daily each day for 14
days and gemcitabine on days 8 and 15 of each cycle, and this was repeated every 21 days. Doses of each drug were planned as
follows: level 1: 800/60, level 2a: 800/80, level 2b: 1000/60, level 3: 1000/80 (gemcitabine (mgm
 2)/S-1 (mgm
 2day
 1)). In all, 21
patients with APC were enrolled. The main grade 3–4 toxicities observed during first cycle were neutropenia (33%), anaemia (10%),
thrombocytopenia (14%) and anorexia (10%). There were no DLT observed in level 1. Three of six patients in level 2a had DLT and
this level was considered the MTD. In all, 12 patients in level 2b had no DLT and this level was selected as the recommended dose.
Applicable responses were one complete response and nine partial responses (48%). As toxicities were well tolerated and
antitumour activities seem to be promising, this combination can be recommended for further phase II studies with APC.
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The incidence and mortality of pancreatic cancer has increased so
rapidly over the past 20 years in Japan that it is now the fifth
leading cause of cancer mortality in the country (Matsuno et al,
2004). The 5-year survival rate is still poor, at less than 10%,
commonly considered to be linked to the high incidence of distant
metastasis even at initial diagnosis, as well as the tumour’s
resistance to anticancer agents. Innovation in systemic chemother-
apy is thus urgently needed to improve the survival of patients
with pancreatic cancer (Glimelius et al, 1996; Evans et al, 1997).
Since 1997, gemcitabine has been the most widely used
chemotherapeutic agent in advanced pancreatic cancer (APC)
and was reported to have significantly better symptom control in
APC compared with 5-FU in a randomised phase III clinical study
(Burris et al, 1997). Even with gemcitabine, however, mono-
therapy has obvious limitations in APC and various combinations
with other agents have been investigated. The combination of
gemcitabine and 5-FU is shown to have a marked synergistic
cytotoxic effect against pancreatic cancer cells in in vitro assay
(Bruckner et al, 1998). Phase I and II studies of combined therapy
of gemcitabine with 5-FU demonstrated superior results (Berlin
et al, 1998, 2000; Cascinu et al, 1999; Hidalgo et al, 1999; Matano
et al, 2000). However, adding weekly intravenous bolus 5-FU to
weekly gemcitabine did not confer a significant survival benefit in
a randomised trial (Berlin et al, 2002). There are no randomised
data on the combination of infusional 5-FU with gemcitabine in
APC.
S-1 is a new oral fluorinated pyrimidine developed by Taiho
Pharmaceutical Co. Ltd (Tokyo, Japan). The agent contains tegafur
(FT), 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium
oxonate (Oxo) in a molar ratio of FT:CDHP:Oxo¼1:0.4:1,
based on a biochemical modulation of 5-FU (Shirasaka et al,
1996a,b). Tegafur, a prodrug of 5-FU, is gradually converted to 5-
FU and is rapidly catabolised by dihydropyridine dehydrogenase
(DPD) in the liver. 5-Chloro-2,4-dihydroxypyridine is a competi-
tive inhibitor of 5-FU catabolism, being about 180 times more
potent than uracil in inhibiting DPD (Tatsumi et al, 1987). When
tegafur is combined with CDHP, the resulting high 5-FU levels are
maintained in both plasma and tumour. In addition, it has been
suggested that CDHP has the potential to enhance the antitumour
activity of 5-FU against subcutaneous tumour in nude mice, using
human pancreas carcinoma cells with a high tumoral DPD activity
(Takechi et al, 2002). Oxo inhibits the enzyme orotate phosphor-
ibosyltransferase, the major enzyme responsible for 5-FU activa-
tion in colon cancer (Peters et al, 1991). Oxo preferentially
localises in the gut rather than in the tumour and has a potential
biochemical effect on the enzyme orotate phosphoribosyltransfer-
ase, thereby selectively inhibiting the formation of 5-FU nucleo-
tides in the gut and theoretically reducing gastrointestinal side
effects (Takechi et al, 1997). In phase II studies for advanced
gastric cancer conducted in Japan, S-1 showed high response rates
of 44–49% (Sakata et al, 1998; Koizumi et al, 2000), and the
usefulness of S-1 was also reported in head and neck (Inuyama
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set al, 2001), breast (Saeki et al, 2004) and colorectal cancer patients
(Ohtsu et al, 2000). In studies outside Japan, the phase II studies of
S-1 against gastric (Chollet et al, 2003) and colorectal cancer (Van
den Brande et al, 2003) in Europe by the EORTC-Early Clinical
Study Group revealed moderate activity. The antitumour activity
of S-1 in patients with pancreatic cancer has not yet been
investigated outside Japan, but preliminary favourable results of S-
1 have been reported in Japanese early phase II study of patients
with APC (Okada et al, 2002).
The administration of oral S-1 is more convenient and simulates
the effect of continuous infusion of 5-FU. We anticipated that
combination chemotherapy of gemcitabine and S-1 would be
effective through the additive and synergistic activity of gemcita-
bine and 5-FU derived from S-1. As yet, the combination regimen
of gemcitabine and S-1 for patients with APC has not been
investigated. Therefore, the author performed a phase I study to
evaluate the safety of treatment combined gemcitabine with S-1
and to determine the maximum tolerated dose (MTD) of each drug
for patients with APC.
PATIENTS AND METHODS
Patient selection
Patients with histopathologically proven APC with distant
metastasis were eligible for the study. Other eligibility criteria
included: 20–74 years of age, Eastern Cooperative Oncology Group
(ECOG) performance status of 2 or less (ambulatory and capable of
self-care), estimated life expectancy of more than 2 months,
adequate renal function (normal serum creatinine and blood urea
nitrogen levels), liver function (total bilirubin level p2.5 times
upper normal limit (UNL) or p3 times UNL after biliary drainage
if the patient had obstructive jaundice and serum transaminases
(GOT, GPT) levels p2.5 times UNL or p3 times UNL), bone
marrow reserve (white blood cell count between 4000 and
12000mm
 3, neutrophil count X2000mm
 3, platelet count
X100000mm
 3 and haemoglobin level X9.5gdl
 1) and pulmon-
ary function (PaO2X70mmHg). If the patients had a previous
history of cancer treatment, that treatment (tumour resection,
chemotherapy, immunotherapy, or radiotherapy) had to have been
discontinued for at least 4 weeks before entry into the study. All
subjects provided written informed consent.
The exclusion criteria were as follows: pulmonary fibrosis or
interstitial pneumonia, marked pleural or pericardial effusion or
marked peripheral oedema, severe heart disease, difficult to
control diabetes mellitus, active infection, pregnant or lactating
females, women of childbearing age unless using effective contra-
ception, severe drug hypersensitivity, metastases to the central
nervous system, severe neurological impairment or mental
disorder, active concomitant malignancy and other serious
medical conditions.
This study was approved by the institutional review board of
Chiba University Graduate School of Medicine.
Study design
This was an open-label, single-centre, nonrandomised, dose-
escalating phase I study. All laboratory tests required to assess
eligibility had to be completed within 7 days prior to the start of
treatment. S-1 was administered orally twice daily after a meal for
14 consecutive days (from the evening of day 1 to the morning of
day 15), followed by a 1-week break. Each capsule of S-1 contained
20 or 25mg of tegafur. Individual doses were rounded down to the
nearest pill size less than the calculated dose, given the available
formulation. Gemcitabine was administered as a 30-min intrave-
nous infusion on days 8 and 15 of each cycle. The cycle was
repeated every 21 days. This schedule was based on an in vitro
study which showed maximum synergy when fluoropyrimidine
precedes exposure to gemcitabine (Rauchwerger et al, 2000). The
dose of each drug in this study was planned as follows: level 1 was
S-1 60mgm
 2day
 1 and gemcitabine 800mgm
 2, level 2a was S-1
80mgm
 2day
 1 and gemcitabine 800mgm
 2, level 2b was S-1
60mgm
 2day
 1 and gemcitabine 1000mgm
 2, level 3 was S-1
80mgm
 2day
 1 and gemcitabine 1000mgm
 2. However, only
when neither level 2a nor level 2b reached the MTD would patients
be assigned to dose level 3.
Definition of dose-limiting toxicities (DLTs) and MTD
Dose-limiting toxicities (DLTs) were determined during the first
treatment cycle. Dose-limiting toxicity was defined, using the
National Cancer Institute (NCI) Common Toxicity Criteria (CTC)
scale (version 2.0), as one or more of the following effects
attributable to study drug: (a) grade 3 or 4 neutropenia
complicated by fever; (b) grade 4 neutropenia lasting longer than
4 days; (c) grade 4 thrombocytopenia; (d) any other grade 3–4
nonhaematologic toxicity except anorexia, nausea and vomiting in
the absence of appropriate antiemetics and (e) delay of recovery
from treatment-related toxicity for more than 2 weeks. At least
three patients were enrolled at each dose level. If DLT was
observed after the first cycle in one or two patients, three
additional patients were placed on that dose level. If only one or
two of six patients experienced DLT, dose escalation would
continue. There was no dose escalation in individual patients. The
MTD of the combination was defined as the dose level that
produced DLT in X3 of six patients or in all of the initial three
patients. The recommended dose (RD) was defined as the dose
level that is one level under MTD considering the toxicity and
tolerability in outpatient setting.
Pretreatment and follow-up studies
Before entry into the study, all patients gave a full history and
underwent a physical examination. A complete blood count (CBC)
with differential, electrolyte levels, and creatinine levels were
measured. Routine chemistry tests, urinalyses and 24-h urine
collections were performed to detect proteinuria. Electrocardio-
grams, chest X-rays and computed tomographic scans of the chest
and abdomen were performed at baseline in all patients.
Additional imaging investigations were performed if clinically
indicated or for disease measurement. A complete blood count
with differential, serum chemistry, creatinine level, and electrolyte
level were measured weekly. Computed tomographic scanning and
imaging of the measurable disease to assess tumour response were
performed every two cycles. At the completion of the study, all
clinical, laboratory, radiologic imaging and other evaluations were
repeated. After completion of the study, patients underwent
follow-up examinations every 2 months until death. Additional
treatment after disease progression was left to the discretion of the
treating physician.
Assessment of efficacy
All patients were included in efficacy measurements on an intent-
to-treat basis. Tumour responses were evaluated according to the
World Health Organization’s criteria (World Health Organization,
1979). A complete response (CR) was defined as the disappearance
of all evidence of cancer for 4 weeks or longer. A partial response
(PR) was defined as a 50% or more reduction in the sum of the
product of the longest perpendicular dimensions of all lesions for 4
weeks or longer without any evidence of new lesions or the
progression of any lesions. Stable disease (SD) was defined as less
than a 50% reduction or less than a 25% increase in the sum of the
product of the longest perpendicular dimensions of all lesions
without any evidence of new lesions. Progressive disease (PD) was
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sdefined as a greater than 25% increase in one or more lesions or
the appearance of any new lesion. To assess objective response,
patients were evaluated every 6 weeks (two cycles) by three
independent radiologists.
Serum CA19-9 levels were measured every 4 weeks during the
chemotherapy using a commercially available chemiluminescent
enzyme immunoassay based on the two-step sandwich method
(CL-EIA). A value of 37Uml
 1 was defined as the upper limit of
the normal.
Overall survival was estimated from the date of first treatment to
death or last follow-up visit, calculated using the Kaplan–Meier
method, and confidence intervals (CI) were based on Greenwood’s
formula.
RESULTS
All 21 patients with APC registered between January 2003 and
March 2004 had primary sites. Out of 21, 18 patients had liver
metastasis except one who had lung metastasis, and two who
presented with peritoneal carcinomatosis only (Table 1). Although
the eligibility criteria included patients who had a previous history
of cancer treatment (tumour resection, chemotherapy, immuno-
therapy, or radiotherapy) before entry into the study, in actuality
no patients had previously received such treatment.
The numbers of patients at each level are shown in Table 2.
Three patients were assigned to dose level 1 without DLT. At dose
level 2a, DLT was observed in two of the first three patients; thus
three additional patients were assigned to this level. Dose-limiting
toxicity was observed in three of six patients, and level 2a reached
MTD. Thus, three patients were assigned to level 2b and no DLT
was observed in the first three patients. However, nine additional
patients were assigned to this level to explore the responses to and
continuity of the treatment.
Toxicity and treatment cycles
The most common toxicities observed during the first cycle of
chemotherapy are listed in Tables 3 and 4. Of three patients in level
1, one had thrombocytopenia of grade 3, but no DLT leading to
MTD was observed in any patient. Of six patients in level 2a, grade
3–4 neutropenia occurred in four patients, grade 3 anaemia in one
patient and grade 3 thrombocytopenia in two patients. In terms of
nonhaematological toxicities, grade 4 anorexia, grade 3 nausea and
grade 3 rash occurred in one patient, each. Three of six patients at
level 2a showed DLT; one patient developed sepsis with grade 4
leukopenia and neutropenia, a second patient developed a grade 3
rash and a third patient developed grade 2 leukopenia, not
recovering within the planned period. Thus, DLT was observed in
three of six patients, and level 2a reached MTD. Of 12 patients at
level 2b, grade 3 to 4 neutropenia occurred in three patients and
grade 3 anaemia in one patient, while grade 3 anorexia occurred in
one patient, and DLT leading to MTD was not observed. Based on
these results, level 2b was selected as the RD for the phase II study
we are to conduct.
The median and range of the treatment cycles and the number of
patients who received a dose reduction were shown in Table 5. The
median number of cycles delivered at dose level 2b, which was
selected as the RD, was four, and only six of 61 cycles at this dose
level needed to reduce their dose of gemcitabine.
Efficacy
Although assessment of tumour response was not a primary
objective of this study, patients were evaluated for tumour
response every two cycles (6 weeks) of the treatment. All 21
patients were assessed for response during this treatment.
Responses in the 21 assessable patients were: one CR (dose level
2a), nine PRs (one at dose level 1, three at dose level 2a and five at
dose level 2b), six stable disease (two at dose level 1, one at dose
level 2a, and three at dose level 2b) and progression in only five
patients (one at dose level 2a and four at dose level 2b). As a result,
10 of the 21 patients (48%) showed complete or PRs (Table 6). The
value of CA 19-9 before treatment was elevated (437Ul
 1)i n1 5
of 21 patients. Of those 15 patients, CA 19-9 decreased 50% or
more compared with the level prior to treatment in seven (47%)
and showed a normal value in three (20%). In contrast, an increase
of CA 19-9 was observed in only four patients (27%). At present,
seven patients are still alive. After a median follow-up of 8.9
Table 1 Patient characteristics
Patients enrolled 21
Men 10
Women 11
Age, years
Median 61
Range 48–73
ECOG status
08
11 1
22
Sites of metastatic disease
Liver 18
Lung 3
Peritoneum 2
Table 2 Dose levels
Dose
level
S-1 (mgm
 2day
 1:
2 weeks)
Gemcitabine (mgm
 2:
on days 8, 15)
No. of
patients
1 60 800 3
2a 80 800 6
2b 60 1000 12
Table 3 Haematological toxicity during first cycle (in all cycles)
No. of patients (cycles) with grade of toxicity
Neutropenia Anaemia Thrombocytopenia
Dose level Total no. of patients (cycles) 1–2 3–4 1–2 3–4 1–2 3–4 DLT
1 3 (27) 2 (13) 0 (5) 3 (5) 0 (1) 2 (6) 1 (5)
2a 6 (66) 2 (34) 4 (22) 5 (15) 1 (5) 4 (13) 2 (13) 2
2b 12 (61) 7 (25) 3 (6) 5 (8) 1 (2) 11 (13) 0 (0)
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smonths (range, 2.2–16.1 months), the median survival time was
9.3 months (95% CI, 6.3–12.3%) and the 1-year survival rate was
35% (95% CI, 12–58%).
DISCUSSION
The primary end point of this trial was to define a chemotherapy
regimen with an acceptable toxicity profile that could potentially
improve the therapeutic efficacy of gemcitabine in patients with
pancreatic cancer. S-1 has been selected as a candidate to be
investigated in combination with gemcitabine in patients with
pancreatic cancer because of its consistent activity as a single agent
in this disease and because of the lack of cross-resistance between
gemcitabine and 5-FU derived from S-1, as suggested by the
observed activity of gemcitabine in patients refractory to 5-FU
(Rothenberg et al, 1996). Also, gemcitabine combined with
infusional 5-FU has been noted to possess synergy in in vitro
cytotoxicity in a variety of malignant cell lines, including
pancreatic cancer (Bruckner et al, 1998). Therefore, we expected
additive and synergistic efficacy by combining gemcitabine with S-
1, hoping that it would mimic the continuous infusion of 5-FU and
also have DPD inhibition, leading to enhancement of antitumour
activity (Takechi et al, 2002).
When considering this study regimen, the authors considered
the possibility that this combination of gemcitabine with S-1 might
produce more severe toxicities than those generated by gemcita-
bine alone. Thus, we tried to lessen the frequency of gemcitabine in
this regimen, administering it twice every 3 weeks. S-1 has already
undergone phase I and II testing in several solid tumours in Japan
and western countries. The DLT was myelosuppression in a
Japanese phase I study (Taguchi et al, 1997), and diarrhoea in a
European and a North-American phase I study (van Groeningen
et al, 2000; Hoff et al, 2003). In Japan, the standard single-agent
dose is 80mgm
 2day
 1 for 28 consecutive days, every 5–6 weeks,
although the RD of S-1 was 70–80mgm
 2 for 28 consecutive days,
every 5 weeks in Europe, and 60mgm
 2 for 28 consecutive days,
every 5 weeks in the US, divided into twice-daily doses.
Consequently, we conducted this study in an attempt to maintain
the same dose intensity as that used in the standard S-1
administration, but in combination with gemcitabine. Both of
the phase II trials in Japan revealed that low grades of
gastrointestinal toxicities, including nausea, vomiting and anor-
exia, and of myelotoxocities such as neutropenia, occurred
frequently during the third week of S-1 administration. Therefore,
we adopted the regimen of S-1 administration for 14 consecutive
days repeated every 3 weeks to avoid severe toxicity. The dose
intensity of S-1 in this regimen amounts to almost the same level as
that in Japanese standard regimen: S-1 for 28 consecutive days,
every 5–6 weeks. Also, given that an in vitro study of pancreatic
cancer cells has also demonstrated maximum synergy for
gemcitabine when exposure to a thymidylate synthase inhibitor
such as 5-FU precedes exposure to gemcitabine (Rauchwerger
et al, 2000), we adopted the regimen of gemcitabine administration
on days 8 and 15 after S-1 administration of each cycle.
Myelosuppression, especially neutropenia, frequently seen in the
combination of continuous infusion 5-FU and gemcitabine, was
predicted as the main toxicity of this study. In this study, the
incidence of grade 3 or 4 neutropenia during the first cycle was
higher than that of other toxicities, with four of six patients at dose
Table 4 Nonhaematological toxicity during first cycle (in all cycles)
No. of patients (cycles) with grade of toxicity
Anorexia Nausea and vomiting Rash
Dose level Total no. of patients (cycles) 1–2 3–4 1–2 3–4 1–2 3–4 DLT
1 3 (27) 1 (2) 0 (0) 1 (1) 0 (0) 3 (6) 0 (0)
2a 6 (66) 1 (4) 1 (2) 1 (5) 1 (2) 3 (7) 1 (1) 1
2b 12 (61) 2 (5) 1 (1) 5 (8) 0 (0) 11 (12) 0 (0)
Table 5 Duration of administration and dose intensity
No. of cycles Cycles with dose reduction in gemcitabine
Dose level S-1/gemcitabine (mgm
 2) No. of patients Total Median (range) No. %
1 60/800 3 27 10 (3–14) 5 19
2a 80/800 6 66 7 (2–20) 31 47
2b 60/1000 12 61 4 (2–10) 6 10
Table 6 Objective tumour response
Response
Dose level No. of patients CR PR SD PD Response rate (%)
Level 1 3 0 1 2 0 33
Level 2a 6 1 3 1 1 67
Level 2b 12 0 5 3 4 42
Total 21 1 965 48
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slevel 2a and three of 12 patients at dose level 2b having grade 3 or 4
neutropenia. On the other hand, the incidence of gastrointestinal
toxicity during the first cycle and all cycles was low. Only one
patient at dose level 2a had grade 4 anorexia and grade 3 nausea,
one patient at dose level 2b had grade 3 anorexia.
A median number of 10 cycles were administered at dose level 1,
seven cycles at dose level 2a and four cycles at dose level 2b.
However, there was no significant difference among the median
number of administered cycles at every dose level. During all
treatment cycles in this study, the incidence of grade 3 or 4
neutropenia at dose level 2b was 10%, at dose level 1 it was 19%,
and at dose level 2a it was 33%. Consequently, only six of 61 cycles
at dose level 2b needed a dose reduction of gemcitabine compared
to 31 of 66 cycles at dose level 2a, which required that.
The first course of chemotherapy was conducted by hospitalisa-
tion for all patients, but the second or subsequent courses could be
performed at an outpatient clinic for 19 of 21 patients. The other
two patients showed early progression of the disease. Moreover,
oral administration of S-1, which eliminates the cost and
inconveniences of infusion pumps and catheters with their
potential risks of infection and thrombosis, also contributes to
fewer hospital visits during this outpatient treatment. Anticancer
treatment for APC would be preferable on an outpatient rather
than an inpatient basis, given the short life expectancy and quality
of life considerations. In treatment for patients with APC, it is
important to not only improve the prognosis of APC but also
create a feasible regimen of chemotherapy that does not require
hospitalization. These results indicated that the combination at the
RDs selected in this study is quite feasible in the outpatient
treatment setting.
In conclusion, this combination chemotherapy with gemcitabine
and S-1 was well tolerated. Although this trial was only a phase I
study to determine the RD and feasibility of such combination,
an encouragingly high response rate has been observed. This
result is very promising, but the survival benefit in comparison
with gemcitabine monotherapy needs to be confirmed in future
studies.
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